Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Linperlisib |
Synonyms | |
Therapy Description |
Linperlisib is a selective small molecule Pik3cd inhibitor, with potential antitumor activity (Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 7531). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Linperlisib | YY 20394|YY-20394|YY20394 | PIK3CD inhibitor 27 | Linperlisib is a selective small molecule Pik3cd inhibitor, with potential antitumor activity (Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 7531). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05274997 | Phase II | Linperlisib | A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | Unknown status | USA | 0 |